1
|
El-Malah AA, Gineinah MM, Khayat MT, Aljahdali AS, Safar MM, Almazmumi HA, Khinkar RM. Design, synthesis, molecular docking, and molecular dynamic studies of novel quinazoline derivatives as phosphodiesterase 7 inhibitors. Front Pharmacol 2024; 15:1389076. [PMID: 38711988 PMCID: PMC11070508 DOI: 10.3389/fphar.2024.1389076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2024] [Accepted: 04/05/2024] [Indexed: 05/08/2024] Open
Abstract
Introduction: Phosphodiesterase 7 (PDE7) is a high-affinity cyclic AMP (cAMP)-specific PDE that is expressed in immune and proinflammatory cells. In this work, we explore the possibility that selective small molecule inhibitors of this enzyme family could provide a novel approach to alleviate the inflammation that is associated with many inflammatory diseases. Methods: A series of novel substituted 4-hydrazinoquinazoline derivatives and fused triazoloquinazolines were designed, synthesized, and evaluated in vitro for their PDE7A inhibition activities, in comparison with Theophylline, a non-selective PDE inhibitor, and BRL50481, a selective PDE7A inhibitor. This series of novel quinazoline derivatives were synthesized via multi-step reactions. The reaction sequence began with selective monohydrazinolysis of compounds 2a,b to give 3a,b. Schiff bases 4a-h were synthesized by the reaction of the quinazolylhydrazines 3a,b with various substituted aromatic aldehydes. The reaction of 4a-h with bromine in acetic acid, in turn, gave fused triazoloquinazolines 5a-h. These compounds were characterized by satisfied spectrum analyses mainly including 1HNMR, 13CNMR, and MS together with elemental analyses. Results and discussion: The results of in vitro PDE7A inhibition activity clearly indicated that compounds 4b, 4g, 5c, and 5f exhibited good potency. Molecular docking and molecular dynamic simulation studies further supported our findings and provided the basis of interaction in terms of conventional hydrogen bonds and π-π stacking patterns. The present results lay the groundwork for developing lead compounds with improved phosphodiesterase seven inhibitory activities.
Collapse
Affiliation(s)
- Afaf A. El-Malah
- Department of Pharmaceutical Chemistry, College of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Magdy M. Gineinah
- Department of Pharmaceutical Chemistry, College of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Maan T. Khayat
- Department of Pharmaceutical Chemistry, College of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Anfal S. Aljahdali
- Department of Pharmaceutical Chemistry, College of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Marwa M. Safar
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Giza, Egypt
- Department of Pharmacology and Biochemistry, Faculty of Pharmacy, The British University in Egypt, Cairo, Egypt
| | - Hadeel A. Almazmumi
- Department of Pharmaceutical Chemistry, College of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Roaa M. Khinkar
- Department of Pharmacy Practice, College of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia
| |
Collapse
|
2
|
Elfeky SM, Sobahi TR, Gineinah MM, Ahmed NS. Synthesis, biological screening, and molecular docking of quinazolinone and quinazolinethione as phosphodiesterase 7 inhibitors. Arch Pharm (Weinheim) 2019; 353:e1900211. [DOI: 10.1002/ardp.201900211] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2019] [Revised: 10/08/2019] [Accepted: 10/16/2019] [Indexed: 12/13/2022]
Affiliation(s)
- Sherin M. Elfeky
- Department of Pharmaceutical Organic Chemistry, Faculty of PharmacyMansoura University Mansoura Egypt
| | - Tariq R. Sobahi
- Department of Chemistry, Faculty of ScienceKing Abdul‐Aziz University Jeddah Saudi Arabia
| | - Magdy M. Gineinah
- Department of Pharmaceutical Organic Chemistry, Faculty of PharmacyMansoura University Mansoura Egypt
- Department of Pharmaceutical Chemistry, Faculty of PharmacyKing Abdul‐Aziz University Jeddah Saudi Arabia
| | - Nesreen S. Ahmed
- Department of Therapeutic Chemistry, Pharmaceutical, and Drug Industries Research DivisionNational Research Center Dokki Cairo Egypt
| |
Collapse
|
3
|
Synthesis and dynamic 1H NMR spectroscopic study of 1,4,6,7,8,9-hexahydro-3-methyl-1,4-diphenyl-7-thioxo-5H-pyrazolo[4′,3′:5,6]pyrido[2,3-d]pyrimidin-5-one. MONATSHEFTE FUR CHEMIE 2017. [DOI: 10.1007/s00706-017-2006-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
4
|
Banerjee A, Narayana L, Raje FA, Pisal DV, Kadam PA, Gullapalli S, Kumar H, More SV, Bajpai M, Sangana RR, Jadhav S, Gudi GS, Khairatkar-Joshi N, Merugu RR, Voleti SR, Gharat LA. Discovery of benzo[d]imidazo[5,1-b]thiazole as a new class of phosphodiesterase 10A inhibitors. Bioorg Med Chem Lett 2013; 23:6747-54. [DOI: 10.1016/j.bmcl.2013.10.027] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2013] [Revised: 10/04/2013] [Accepted: 10/17/2013] [Indexed: 01/19/2023]
|
5
|
Kilburn JP, Kehler J, Langgård M, Erichsen MN, Leth-Petersen S, Larsen M, Christoffersen CT, Nielsen J. N-Methylanilide and N-methylbenzamide derivatives as phosphodiesterase 10A (PDE10A) inhibitors. Bioorg Med Chem 2013; 21:6053-62. [DOI: 10.1016/j.bmc.2013.07.030] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2013] [Revised: 07/09/2013] [Accepted: 07/12/2013] [Indexed: 10/26/2022]
|
6
|
The discovery of potent, selective, and orally active pyrazoloquinolines as PDE10A inhibitors for the treatment of Schizophrenia. Bioorg Med Chem Lett 2012; 22:1019-22. [DOI: 10.1016/j.bmcl.2011.11.127] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2011] [Revised: 11/29/2011] [Accepted: 11/30/2011] [Indexed: 01/06/2023]
|
7
|
Redondo M, Zarruk JG, Ceballos P, Pérez DI, Pérez C, Perez-Castillo A, Moro MA, Brea J, Val C, Cadavid MI, Loza MI, Campillo NE, Martínez A, Gil C. Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model. Eur J Med Chem 2012; 47:175-85. [DOI: 10.1016/j.ejmech.2011.10.040] [Citation(s) in RCA: 55] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2011] [Revised: 10/18/2011] [Accepted: 10/21/2011] [Indexed: 12/31/2022]
|
8
|
Kehler J, Ritzen A, Langgård M, Petersen SL, Farah MM, Bundgaard C, Christoffersen CT, Nielsen J, Kilburn JP. Triazoloquinazolines as a novel class of phosphodiesterase 10A (PDE10A) inhibitors. Bioorg Med Chem Lett 2011; 21:3738-42. [DOI: 10.1016/j.bmcl.2011.04.067] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2011] [Revised: 04/12/2011] [Accepted: 04/15/2011] [Indexed: 10/18/2022]
|
9
|
Asproni B, Murineddu G, Pau A, Pinna GA, Langgård M, Christoffersen CT, Nielsen J, Kehler J. Synthesis and SAR study of new phenylimidazole-pyrazolo[1,5-c]quinazolines as potent phosphodiesterase 10A inhibitors. Bioorg Med Chem 2011; 19:642-9. [DOI: 10.1016/j.bmc.2010.10.038] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2010] [Revised: 10/11/2010] [Accepted: 10/14/2010] [Indexed: 01/21/2023]
|
10
|
Kelly MP, Brandon NJ. Differential function of phosphodiesterase families in the brain: gaining insights through the use of genetically modified animals. PROGRESS IN BRAIN RESEARCH 2009; 179:67-73. [PMID: 20302819 DOI: 10.1016/s0079-6123(09)17908-6] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Phosphodiesterases (PDEs) are the only known enzymes to degrade cAMP and cGMP, intracellular signaling molecules key to numerous cellular functions. There are 11 PDE families identified to date, and each is expressed in a unique pattern across brain regions. Here, we review genetic mouse models in which PDEs are either directly manipulated (e.g., genetically deleted) or are changed in a compensatory manner due to the manipulation of another target. We believe these genetic mouse models have contributed to our understanding of how the PDE1, PDE4, and PDE10 families contribute uniquely to overall brain function.
Collapse
|
11
|
Deninno MP, Andrews M, Bell AS, Chen Y, Eller-Zarbo C, Eshelby N, Etienne JB, Moore DE, Palmer MJ, Visser MS, Yu LJ, Zavadoski WJ, Michael Gibbs E. The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents. Bioorg Med Chem Lett 2009; 19:2537-41. [PMID: 19339180 DOI: 10.1016/j.bmcl.2009.03.024] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2009] [Revised: 03/05/2009] [Accepted: 03/09/2009] [Indexed: 11/24/2022]
Abstract
Starting from a non-selective pyrazolo-pyrimidone lead, the sequential use of parallel medicinal chemistry and directed synthesis led to the discovery of potent, highly selective, and orally bioavailable PDE9 inhibitors. The availability of these tools allowed for a thorough evaluation of the therapeutic potential of PDE9 inhibition.
Collapse
Affiliation(s)
- Michael P Deninno
- Pfizer Global Research and Development, Groton Laboratories, Groton, CT 06340, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Gil C, Campillo NE, Perez DI, Martinez A. PDE7 inhibitors as new drugs for neurological and inflammatory disorders. Expert Opin Ther Pat 2008. [DOI: 10.1517/13543776.18.10.1127] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|